What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? - Wikidata - wikimedia - TriplyDB

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

http://www.wikidata.org/entity/Q39154057

about

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

http://www.wikidata.org/entity/Q39154057

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@en

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@nl

type

label

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@en

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@nl

prefLabel

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@en

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@nl

P1433

Q39154057-0C4D7F71-2884-4F45-BC3E-8909A5C811D3

P1476

Q39154057-238146FA-EDB3-485D-B9B0-4FD43F704559

P2093

Q39154057-D92DF1B7-8C8C-454A-803E-66CFCF0DB6ED

P2860

Q39154057-0468A9C3-1E8B-4EDE-9520-B7D57503916D

Q39154057-0FD8A574-9B00-4EE7-A3B0-31302E65648A

Q39154057-20629ADD-08F0-43DF-A903-4F2B7A3A4CF1

Q39154057-3FB6FA75-C184-4EF7-AB0D-EC428DF0D7A6

Q39154057-564B0AEA-C3BF-4DAB-9F21-9056184EE59A

Q39154057-564C11A3-ADDB-4A90-9826-31AE01A6E143

Q39154057-5F16DA85-B6A6-43FB-80A9-E1A04EFCD53C

Q39154057-6CE58F28-364D-4E08-ABB1-CD1BFE82D5A6

Q39154057-7D58F6FE-A14B-4378-A495-6FFA91DCEC16

Q39154057-7F782940-9D6F-455D-8144-D82FC4537950

P2888

Q39154057-41E7A22B-1F07-4EF7-AC04-2E061247D61E

P304

Q39154057-004EB131-68CB-4BF2-AC8A-5D1CBCB5A5E3

P31

Q39154057-0CC4CFA0-7309-4F6A-A486-5C4C469A9A16

P356

Q39154057-9D7C52F6-8FCC-4B75-A60E-90F1C4FFB3AF

P433

Q39154057-9C2012B2-CDD1-46B4-8990-184365284BC9

P478

Q39154057-C446C750-1F38-433E-AB78-617F3A3C437B

P50

Q39154057-1BA3ADFF-DF1B-49AE-806B-BF57D6526B11

P577

Q39154057-981ED1A4-BE62-418D-AE36-D60D414EFDF0

P698

Q39154057-68C0A1C3-7BB2-4456-9AAD-D2D38D13D58F

P921

Q39154057-F05A8936-AD5B-46A4-AE63-030F533D3968

P356

S11864-017-0450-8

P1433

Current Treatment Options in Oncology

P1476

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

@en

P2093

Benjamin N Voorhies

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Genomic aberrations and survival in chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

P2888

s11864-017-0450-8

P304

12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-017-0450-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Deborah M Stephens

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28243993

http://www.w3.org/2001/XMLSchema#string

P921